Discovery & Industry Partners

NYB signed a Memorandum of Understanding (MoU) with U.S.-based Precisya Global to integrate genomic analysis with natural compound research, leveraging AI-driven matching and comprehensive validation processes to expedite the development of plant-based treatments for genetic conditions. 

NYB’s AI-first compound discovery platform will screen its extensive library of plant-based compounds, while Precisya Global Inc will augment this process by supplying secure access to anonymized patient genomic data and advanced bioinformatic analysis, enabling the correlation of compound responses with specific genetic variants.

What This Collaboration Delivers

• Preclinical validation using biobank data and molecular docking
• In vitro and in vivo testing
• Co-development of gene-informed formulations